AZ 1569
Alternative Names: AZ'1569Latest Information Update: 29 Jul 2022
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Queens University Belfast; Royal College of Surgeons
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer